News BeepSep 1, 2025

Triptorelin associated adverse events evaluated using FAERS pharmacovigilance data

Our pharmacovigilance study represents the first comprehensive analysis of triptorelin’s post-marketing safety profile using FAERS data. The identificationof…
#NewsBeep #News #Headlines #Adverseevents #Cancer #endocrinology #FAERS #HumanitiesandSocialSciences #Latvia #LV #Medicalresearch #multidisciplinary #Pharmacovigilance #Science #Triptorelin
https://www.newsbeep.com/95734/

News BeepSep 1, 2025

A disproportionality analysis of real-world adverse events associated with tirofiban from the FAERS database

Tirofiban, as a GP IIb/IIIa receptor antagonist, competitively inhibits the bridging of platelets via fibrin, which is the…
#NewsBeep #News #Headlines #Adverseevent #bleeding #cardiology #Disproportionalityanalysis #FAERS #HumanitiesandSocialSciences #Latvia #LV #Medicalresearch #multidisciplinary #Neurology #Science #Tirofiban
https://www.newsbeep.com/95720/

PlanetMedicinesJul 7, 2024
https://pubmed.ncbi.nlm.nih.gov/38957734/ Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System (Makunts, et al, 2024) #mdma #dili #liver #psychedelic #psychedelicresearch #faers #fda #psychedelics #mdmaassistedtherapy — finding in estimated 20 million, perhaps 1 case of liver damage from MDMA, increased risk with poly drug use.
Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System - PubMed

3,4-Methylenedioxymethamphetamine (MDMA) is being investigated in controlled clinical trials for use as an adjunct medication treatment for post-traumatic stress disorder. MDMA is metabolized by N-demethylation, primarily by CYP2D6, to its main inactive metabolite, 4-hydroxy-3-methoxymethamphetamine …

PubMed